{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-001394","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.696689+00:00","generated_at":"2026-05-23T08:28:33.680621+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silexion partners with Catalent for siRNA formulation and manufacturing of SIL204","bullets":["Collaboration with Catalent for SIL204 formulation development and clinical manufacturing at Limoges, France facility.","SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, G13D) in pancreatic, colorectal, and lung cancers.","Company plans to initiate human clinical trials for SIL204 in first half of 2026.","Preclinical data showed significant reduction in primary tumor growth and metastatic spread in pancreatic cancer models.","Regulatory submissions to Israel Ministry of Health expected H2 2025 and to EU in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-001394","json":"https://secwatch.observer/filing/0001178913-25-001394.json","markdown":"https://secwatch.observer/filing/0001178913-25-001394.md","text":"https://secwatch.observer/filing/0001178913-25-001394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001394/0001178913-25-001394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001394/zk2533046.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:28:33.680621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}